<div id="readability-page-1"><p>Allworth Financial LP increased its holdings in shares of  Merck &amp; Co., Inc. (NYSE:MRK - Free Report) by 71.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor  owned 211,931 shares of the company's stock after purchasing an additional 88,256 shares during the quarter. Allworth Financial LP's holdings in Merck &amp; Co., Inc. were worth $22,308,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Merck &amp; Co., Inc.</strong> alerts:</span></p></div><ul><li>Merck Just Made a Big Bet on a New Cancer Growth Engine </li></ul><p>Other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in  Merck &amp; Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock valued at $3,808,000 after buying an additional 8,710 shares in the last quarter.  Sivia Capital Partners LLC grew its holdings in  Merck &amp; Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company's stock valued at $910,000 after buying an additional 3,941 shares in the last quarter.  Diversify Advisory Services LLC grew its holdings in  Merck &amp; Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company's stock valued at $2,590,000 after buying an additional 15,636 shares in the last quarter.  Diversify Wealth Management LLC grew its holdings in  Merck &amp; Co., Inc. by 22.2% during the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company's stock valued at $3,054,000 after buying an additional 6,897 shares in the last quarter.  Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in  Merck &amp; Co., Inc. by 111.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company's stock valued at $53,918,000 after buying an additional 359,356 shares in the last quarter. Hedge funds and other institutional investors own  76.07% of the company's stock. </p><h2>Merck &amp; Co., Inc. Price Performance</h2><p>NYSE:MRK opened at $113.21 on Friday. The firm has a market capitalization of $279.60 billion, a price-to-earnings ratio of 31.89, a PEG ratio of 2.55 and a beta of 0.18. Merck &amp; Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The business has a 50 day simple moving average of $116.18 and a 200-day simple moving average of $109.19. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. </p><ul><li>3 Undervalued Names Too Cheap to Ignore</li></ul><p>Merck &amp; Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck &amp; Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company's revenue for the quarter was up 4.9% on a year-over-year basis. During the same period last year, the company earned $2.22 EPS. Merck &amp; Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS.  Equities analysts forecast that  Merck &amp; Co., Inc. will post 5.16 EPS for the current year. </p><h2>Analyst Ratings Changes</h2><p>Several equities analysts have weighed in on MRK shares. UBS Group raised their price target on Merck &amp; Co., Inc. from $130.00 to $145.00 and gave the company a &#34;buy&#34; rating in a report on Monday, April 13th. Guggenheim raised their price target on Merck &amp; Co., Inc. from $122.00 to $140.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 6th. Zacks Research upgraded Merck &amp; Co., Inc. from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, March 17th. Barclays started coverage on Merck &amp; Co., Inc. in a research note on Friday, February 20th. They issued an &#34;overweight&#34; rating and a $140.00 price objective for the company. Finally, Citigroup started coverage on Merck &amp; Co., Inc. in a research note on Wednesday, May 6th. They issued a &#34;neutral&#34; rating and a $125.00 price objective for the company. One equities research analyst  has rated the stock with a Strong Buy rating, eleven have assigned  a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, Merck &amp; Co., Inc. currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $128.18.</p><ul><li>3 “Forever Stocks” to Hold When the Market Won’t Sit Still</li></ul><p><b>View Our Latest Stock Report on MRK</b></p><h2>Merck &amp; Co., Inc. News Summary</h2><p>Here are the key news stories impacting Merck &amp; Co., Inc. this week:</p><ul>   <li><span>Positive Sentiment: </span>Zacks highlighted that Keytruda continues to be a major growth driver for Merck, with strong first-quarter sales and potential upside from new indications and combination therapies in 2026. <i></i><span>Article Title</span></li>    <li><span>Neutral Sentiment: </span>Merck is being discussed in a broader biotech/biopharma context, including Veeva’s upcoming summit where Merck will participate in AI and commercial strategy discussions. This is more of an industry event than a direct earnings or pipeline catalyst. <i></i><span>Article Title</span></li>    <li><span>Neutral Sentiment: </span>Separate commentary noted that Merck has attracted investor attention on Zacks and that recent share-price performance has been mixed, which may be keeping traders focused on valuation rather than prompting a fresh buy or sell signal. <i></i><span>Article Title</span></li>    <li><span>Neutral Sentiment: </span>Another market note said Merck’s short-term momentum has cooled after recent weakness, even though longer-term performance remains strong. That suggests investors are weighing the recent pullback against the company’s solid fundamentals. <i></i><span>Article Title</span></li> </ul><h2>Merck &amp; Co., Inc. Profile</h2> (Free Report)<p>Merck &amp; Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.  </p><p>Founded in the late 19th century as the U.S.</p><h2>See Also</h2><ul><li>Five stocks we like better than Merck &amp; Co., Inc.</li><li>YETI Rallies After Earnings Beat and Raised Outlook</li><li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li><li>Cisco’s Vertical Rally May Still Be in the Early Innings</li><li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li></ul><p><strong>Want to see what other hedge funds are holding MRK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck &amp; Co., Inc. (NYSE:MRK - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Merck &amp; Co., Inc. Right Now?</h2><p>Before you consider Merck &amp; Co., Inc., you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck &amp; Co., Inc. wasn't on the list.</p><p>While Merck &amp; Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

<p>Allworth Financial LP increased its stake in Merck & Co., Inc. (NYSE:MRK) by 71.4% in Q4, owning 211,931 shares valued at $22.3 million. Other investors also raised their holdings. Merck's stock opened at $113.21, with a market cap of $279.6 billion. The company reported Q1 earnings of ($1.28) EPS, beating estimates, and revenue of $16.29 billion, up 4.9% year-over-year. Analysts have set price targets between $125 and $145, with a mix of ratings from Strong Buy to Hold.</p>

Market Beat

Merck

ALPS Medical Breakthrough

VanEck Biotech ETF

iShares US Pharma

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

VG Health

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

UBS Group AG

Barclays

Citigroup

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Allworth Financial LP Grows Stake in Merck & Co., Inc. $MRK